Samsung Looks To Nix Further Regeneron Eye Med Patents
Samsung Bioepis has joined the queue of pharma companies looking to revoke two key eye medicine patents belonging to Regeneron, arguing in a London court that the treatment is neither new...To view the full article, register now.
Already a subscriber? Click here to view full article